November 30, 2023

IntegriChain GTN Experts to Speak at Informa’s Pharma/BioTech GTN Summit

Philadelphia, PA, November 13, 2023 – IntegriChain, delivering pharma’s only comprehensive technology, data, consulting, and outsourcing platform for data-driven commercialization, today announced that its Gross-to-Net (GTN) experts will present at Informa’s upcoming Pharma | Biotech GTN Summit. Jen Sharpe, Vice President of Gross-to-Net Operational Consulting and facilitator of the Revenue Analytics Collaborative, and Jeff Baab, Vice President of Operational Consulting, have extensive experience in GTN automation, advising Pharma manufacturers of all sizes, business stages, and complexity on SaaS and BPaaS solutions for GTN forecasting, accruals, and analytics. Jen Sharpe is Chairperson and IntegriChain is a sponsor of the conference, which runs November 13 to 15 in Philadelphia.

Details of IntegriChain’s sessions during the conference are as follows.

Monday, November 13
Revenue Analytics Collaborative Hot Topics
4:30 – 5:30 pm
Jen Sharpe, Moderator

This interactive roundtable session is hosted by the Revenue Analytics Collaborative, IntegriChain, and various participating sponsors.

Tuesday, November 14
Keynote: Navigating the Evolving Regulatory and Financial Landscape — Key Considerations and  Recommendations for IRA, the AMP Cap Removal and Future Drug Policy Proposals
8:45 – 9:45 am

Jeff Baab, Moderator
Anthony Fiordaliso, Vice President, US Commercial Contracts & Pricing, Abbvie
Chris Sloan, Director, Market Access Strategy, Blueprint Medicines
Sean Dickson, Senior Vice President, Pharmaceutical Policy and Strategy, America’s Health Insurance Plans
Chris Schott, Partner, Latham & Watkins

This session explores the latest developments for the IRA, CMS, and AMP cap removal and their implications; discusses top tips and pitfalls to avoid when ensuring regulatory financial compliance and planning; and maps the political and legislative landscape and what’s on the horizon.

Technological advancements in GTN management: From automation to AI, leveraging innovation for effective GTN optimization
9:45 – 10:45 am

Jen Sharpe, Moderator
Frank Panaro, Director, Corporate Finance, Sunovion Pharmaceuticals
Ekaterina Miteiko, Associate Director, Financial Planning & Analytics, Operations & Strategy, Mitsubishi Tanabe Pharma America, Inc.
Kary Callahan, Director, Finance, Paratek Pharmaceuticals
Rochelle Cupelli, VP, Finance, Ironshore Pharmaceuticals
Melissa Nortom, Assistant Controller, Revenue, Tolmar
George Kappus, Associate Director, M&S Controlling (GtN), Boehringer Ingelheim

This session explores how to assess a company’s GTN needs, including the use of automation, cloud, and software in supporting GTN. It will explore the pros and cons of in-house and  outsourced solutions, as well as the impact of AI have on analytics and forecasting. In addition, the session will discuss how manufacturers can have capable processes, cross-functional collaboration, and talent in place to support technology implementation.

IRA Impacts on GTN: Changing Policy and Drug Pricing Proposals
Jeff Baab
11:25 am – 12:25 pm
This session will tap into Baab’s extensive expertise on the impact of the Inflation Reduction Act on drug pricing and GTN.

About IntegriChain’s Gross-to-Net Solutions and Operational Consulting Programs
IntegriChain offers a full suite of Gross-to-Net Solutions and Operational Consulting programs, including:

GTN Accrual Management. An end-to-end solution for Market Access and Finance departments, pre-configured for all standard line items with robust out-of-the-box accrual methodologies, including inventory and pipeline adjustments to accruals, balance sheet reconciliation to ERP systems, and true-up functionality.

GTN Accrual Forecasting. Based on industry-standard forecast methodologies configured for each liability line item with the ability to execute multiple scenario analyses for forecasts along with functionality to compare scenarios to improve forecast accuracy, GTN modeling, and financial close efficiency.

GTN Analytics. Delivering visibility to comprehensive market access datasets that power the accuracy of GTN accruals and forecasting processes, best practices GTN reports and metrics, and visualizations of GTN trends that allow for better accrual and net-price predictability and decision-making.

GTN Operational Consulting. IntegriChain industry experts routinely advise manufacturers on GTN readiness for launch, GTN process assessments, and GTN market analysis.

About the Revenue Analytics Collaborative
The RAC comprises more than 800 Life Sciences business and financial professionals who own, support and analyze Commercial, Government, GTN, and Trade/Channel data, processes and systems in Pricing & Contracting, Pre-Deal Analytics & Performance Monitoring, Rebate & Chargeback Management & Adjudication; Government Pricing Reporting & Analytics, GTN Channel Forecasting & Scenario Modeling; GTN Accrual & Balance Sheet Management, Report, and Analytics, as well as Trade & Channel. The collaborative facilitates timely and relevant knowledge sharing via anonymous Collab forums, benchmarking, colleague connect for networking, lunch & learns, webinars, and the annual RAC Summit. For details or to join, visit 

About IntegriChain
About IntegriChain
IntegriChain helps pharma manufacturers bring their science to market, ensuring patients have affordable, timely, and sustainable access to therapy. IntegriChain delivers Pharma’s only data-driven commercialization platform — from strategy to operational execution. The Company’s unique focus on data, technology, consulting, and outsourcing helps connect the commercial, financial, and operational dimensions of drug access and profitability. Through the ICyte Platform, IntegriChain enables pharmaceutical innovators to achieve better commercial outcomes by digitalizing daily and recurring business activities and by integrating data and operations across contracting, pricing, channel and distribution, and gross-to-net. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm, and is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit or follow on LinkedIn.

Jennifer Guinan, Sage Strategic Marketing, 610.410.8111,

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article